Searching... Searching...
  • NVP + 3.69%
  • Köp 2.36
  • Sälj 2.38
  • Senast 2.39
  • SEK

  • NEVPF +NA
  • Buy NA
  • Sell NA
  • Latest NA
  • USD

Legal Disclaimer – Prospectus 2018

The information and documents on this part of NeuroVive Pharmaceutical AB’s (publ) (“NeuroVive”) website may not, according to law and regulations, be made available to certain persons, and consequently, persons whom wish to access the information and documents must inform themselves of and act in accordance with such restrictions. We ask you to read the text below and submit the following confirmation every time you want to enter this website. Your confirmation must be true.

This material is not intended for and must not be accessed by persons resident or located in the United States of America, Australia, Canada, Hong Kong, Japan, New Zealand, Singapore, South Africa, Switzerland or in any other country where participation in NeuroVive’s rights issue or purchase or sale of unit rights, paid subscribed units, newly issued shares or warrants is not permitted.

The offer to acquire units in NeuroVive according to the prospectus is not being made to persons whose participation in the offer requires additional prospectuses, registration measures or any other measures in addition to those required under Swedish law. The prospectus and other related documents may not be distributed in or to any country where such distribution or the offer requires such additional measures or would be in conflict with any laws or regulations in such country. Unit rights, paid subscribed units, newly issued shares or warrants have not been registered or will not be registered under the United States Securities Act of 1933 in its current version or under any applicable law in the United States of America, Australia, Canada, Hong Kong, Japan, New Zealand, Singapore, South Africa, Switzerland or in any other country where the offer to acquire units in NeuroVive or distribution of the prospectus constitute a violation of applicable laws or regulations, or require that additional prospectuses are prepared or registered or that other measures are taken in addition to those required under Swedish law. A notification to acquire units in violation of the above may be considered invalid and consequently ignored.

By accepting below, I confirm that I have read and accepted to be bound by the information, instructions, terms and conditions provided on this part of the website and confirm that I am not located in the United States of America, Australia, Canada, Hong Kong, Japan, New Zealand, Singapore, South Africa, Switzerland or in any other jurisdiction in which distribution or participation in the offer would be in conflict with any laws or regulations in such jurisdiction or where participation in the offer requires additional prospectuses, registration measures or any other measures in addition to those required under Swedish law.

Yes, I agree                        No, I do not agree

Comments are closed.

  • Press Releases

    NeuroVive presents NVP025 mitochondrial myopathy project progress at Mitochondrial Medicine conference 20 April Lund, Sweden, 20 April 2018, NeuroVive Pharmaceutical AB ... Read More